Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

[1]  H. Hurwitz,et al.  Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. , 2003, Seminars in oncology.

[2]  N. Assy,et al.  Vascular endothelial growth factor and angiopoietin in liver regeneration. , 2001, Biochemical and biophysical research communications.

[3]  M. Gonen,et al.  Influence of Transfusions on Perioperative and Long-Term Outcome in Patients Following Hepatic Resection for Colorectal Metastases , 2003, Annals of surgery.

[4]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[5]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Abalı,et al.  Bevacizumab, bleeding, thrombosis, and warfarin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Schwartz,et al.  Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Robert C. G. Martin,et al.  Quality of Complication Reporting in the Surgical Literature , 2002, Annals of surgery.

[9]  Yuman Fong,et al.  Improvement in Perioperative Outcome After Hepatic Resection: Analysis of 1,803 Consecutive Cases Over the Past Decade , 2002, Annals of surgery.

[10]  J. Berlin,et al.  Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery , 2004 .

[11]  C. Couinaud.  [Anatomic principles of left and right regulated hepatectomy: technics]. , 1954, Journal de chirurgie.

[12]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[13]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Berlin,et al.  Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A Messori,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[18]  F. Kabbinavar,et al.  Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[21]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[22]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[23]  L. Andrini,et al.  Chronobiology of the proliferative events related to angiogenesis in mice liver regeneration after partial hepatectomy , 2003, Cell biology international.

[24]  M. Shah,et al.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Catalano,et al.  High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 , 2005 .

[26]  M. Dewhirst,et al.  SU5416 delays wound healing through inhibition of TGF-beta 1 activation. , 2002, Cancer biology & therapy.

[27]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[28]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[29]  Kenneth J. Hillan,et al.  Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.

[30]  V. Rubin.  Women's Work. , 1986 .

[31]  M. Dewhirst,et al.  SU5416 Delays Wound Healing Through Inhibition of TGF-β Activation , 2002 .

[32]  C. Couinaud.  Bases anatomiques des hépatectomies gauche et droite réglées: techniques qui en découlent. , 1954 .